| Literature DB >> 26305256 |
Arbace Officioso1,2, Caterina Manna2, Kousi Alzoubi3, Florian Lang4.
Abstract
The cholesterol synthesis inhibitor Triparanol has been shown to trigger apoptosis in several malignancies. Similar to the apoptosis of nucleated cells, erythrocytes may enter eryptosis, the suicidal death characterized by cell shrinkage and cell membrane scrambling with phosphatidylserine translocation to the erythrocyte surface. Triggers of eryptosis include oxidative stress which may activate erythrocytic Ca(2+) permeable unselective cation channels with subsequent Ca(2+) entry and increase of cytosolic Ca(2+) activity ([Ca(2+)]i). The present study explored whether and how Triparanol induces eryptosis. To this end, phosphatidylserine exposure at the cell surface was estimated from annexin-V-binding, cell volume from forward scatter, hemolysis from hemoglobin release, [Ca(2+)]i from Fluo3-fluorescence, and ROS formation from 2',7'-dichlorodihydrofluorescein diacetate (DCFDA) dependent fluorescence. As a result, a 48 h exposure of human erythrocytes to Triparanol (20 µM) significantly increased DCFDA fluorescence and significantly increased Fluo3-fluorescence. Triparanol (15 µM) significantly increased the percentage of annexin-V-binding cells, and significantly decreased the forward scatter. The effect of Triparanol on annexin-V-binding was significantly blunted, but not abolished by removal of extracellular Ca(2+). In conclusion, Triparanol leads to eryptosis, the suicidal erythrocyte death characterized by cell shrinkage and phospholipid scrambling of the erythrocyte cell membrane. Triparanol is at least in part effective by stimulating ROS formation and Ca(2+) entry.Entities:
Keywords: calcium; cell volume; eryptosis; oxidative stress; phosphatidylserine
Mesh:
Substances:
Year: 2015 PMID: 26305256 PMCID: PMC4549755 DOI: 10.3390/toxins7083359
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1Effect of Triparanol on phosphatidylserine exposure (a) Original histogram of annexin-V-binding of erythrocytes following exposure for 48 h to Ringer solution without (grey area) and with (black line) presence of 20 µM Triparanol; (b) Arithmetic means ± SEM (n = 4) of erythrocyte annexin-V-binding (black bars) following incubation for 48 h to Ringer solution without or with presence of Triparanol (5–40 µM). *** (p < 0.001) indicate significant difference from the absence of Triparanol (ANOVA).
Figure 2Effect of Triparanol on erythrocyte forward scatter (a) Original histogram of forward scatter of erythrocytes following exposure for 48 h to Ringer solution without (grey area) and with (black line) presence of 20 µM Triparanol; (b) Arithmetic means ± SEM (n = 4) of the erythrocyte forward scatter (FSC) following incubation for 48 h to Ringer solution without (white bar) or with (black bars) Triparanol (5–40 µM). *** (p < 0.001) indicate significant difference from the absence of Triparanol (ANOVA).
Figure 3Effect of Triparanol on erythrocyte Ca2+ activity (a) Original histogram of Fluo3-fluorescence in erythrocytes following exposure for 48 h to Ringer solution without (grey area) and with (black line) presence of Triparanol (20 µM); (b) Arithmetic means ± SEM (n = 4) of the Fluo3-fluorescence (arbitrary units) in erythrocytes exposed for 48 h to Ringer solution without (white bar) or with (black bars) Triparanol (5–20 µM). *** (p < 0.001) indicate significant difference from the absence of Triparanol (ANOVA).
Figure 4Ca2+ sensitivity of Triparanol-induced phosphatidylserine exposure (a) Original histogram of annexin-V-binding of erythrocytes following exposure for 48 h to Ringer solution without (grey area) and with (black line) presence of Triparanol (20 µM) in the presence; and absence (b) of extracellular Ca2+; (c) Arithmetic means ± SEM (n = 4) of annexin-V-binding of erythrocytes after a 48 h treatment with Ringer solution without (white bars) or with (black bars) Triparanol (20 µM) in the presence (left bars, +Ca2+) and absence (right bars, −Ca2+) of Ca2+. *** (p < 0.001) indicates significant difference from the absence of Triparanol, ### (p < 0.001) indicate significant difference from the presence of Ca2+ (ANOVA).
Figure 5Effect of Triparanol on erythrocyte ROS formation (a) Original histogram of 2’,7’-dichlorodihydrofluorescein diacetate (DCFDA) fluorescence in erythrocytes following exposure for 48 h to Ringer solution without (grey area) and with (black line) presence of Triparanol (20 µM); (b) Arithmetic means ± SEM (n = 4) of the DCFDA fluorescence (arbitrary units) in erythrocytes exposed for 48 h to Ringer solution without (white bar) or with (black bars) Triparanol (5–20 µM). ** (p < 0.01), *** (p < 0.001) indicate significant difference from the absence of Triparanol (ANOVA).